Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Specimen Handling 184Magnetic Resonance Spectroscopy 139Biopsy 102Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28X-Rays 27pembrolizumab 26Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Proton Therapy × 30 days × Clear all
NCT04671667 2026-06-05

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
188 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡